FindTrial
Sign In

Analgesic effect of dexmedetomidine combined with ropivacaine for ultrasound-guided thoracic paravertebral block in patients with herpes zoster neuralgia

Analgesic effect of dexmedetomidine combined with ropivacaine for ultrasound-guided thoracic paravertebral block in patients with herpes zoster neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021129
Enrollment
Unknown
Registered
2019-01-29
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

Group 1:ropivacaine
Group 2:ropivacaine plus dexmedetopyrimidine

Sponsors

First Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Herpes zoster neuralgia within 3 months of onset (chest) 2. Age 18-70; 3. NRS greater than 3.

Exclusion criteria

Exclusion criteria: 1. Infection and hematoma at puncture site; 2. BP < 90/60 mmHg, HR < 50 times/min; 3. Coagulation dysfunction. 4. Known allergic history of local anesthetics and dexmedetomidine; 5. Severe liver and kidney dysfunction; 6. Mental and psychological disorders, unable to clearly express pain NRS score

Design outcomes

Primary

MeasureTime frame
Pain score (NRS);—

Secondary

MeasureTime frame
GAD-7;PHQ-9;blood pressure;Sleep score;heart rate;Pulse oxygen saturation;Ramsay score;—

Countries

China

Contacts

Public ContactZhiyou Peng

First Affiliated Hospital, School of Medicine, Zhejiang University

464105001@qq.com+86 0571 87235147

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026